First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms

Thomas S, Wermke M, Vucinic V, Wagner-Drouet E, Mackensen A, Zeiser R, Bug G, Schmitt M, Herr W, Prinz PU, Burdek M, Raffegerst S, Tafuri A, Geiger C, Crame K, Goedkoop R, Pinkernell K, Schendel DJ. First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. Cancers (Basel). 2025 Sep 11. 17doi:10.3390/cancers17182968. PMID: 41008812